Abstract
HIV-1 group O (HIV-1/O) is a divergent group of HIV-1 variants that is endemic in Cameroon, representing 1% of all HIV-1 infections.1 Most strains of this group display the natural Y181C resistance-associated mutation to non-nucleoside reverse transcriptase inhibitors, limiting the antiretroviral (ARV) therapeutic combinations available for infected patients.2 Bictegravir (BIC) is an integrase strand transfer inhibitor (INSTI), a therapeutic class of ARV that is today recommended as first-treatment and/or switch.3 This molecule is co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) in BIKTARVY® (Gilead®, 2018). Previous data on the phenotypic susceptibility of HIV-1/O to bictegravir demonstrated complete in vitro susceptibility: 100% of the panel of 41 HIV-1/O strains had a fold change of <5, but these results need to be confirmed with clinical data in vivo.4 Our aim was to evaluate the virological response of patients receiving a combination of BIC/FTC/TAF in a French cohort...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
